Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Further, an upregulation of PD-1 on sTILs of residual disease and a decline ... patients with treatment-naïve nonmetastatic HER2-positive breast cancer. Patients needed to have an Easter ...

The KATHERINE trial included 1,486 patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who had residual invasive disease in the breast or axillary lymph node ...

Launched in 2012, the multinational KATHERINE trial involved almost 1,500 women with HER2-positive breast cancer and residual disease in the breast or axillary lymph nodes after neoadjuvant ...

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial Trastuzumab Emtansine for Residual ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Residual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy (NAC) had a higher ...

An early-stage HER2-positive (HER2+) breast cancer is always a shock, but today’s treatment options should give you hope. Over the past 2 decades, advances in medicine have brought us new ...

HER2-positive breast cancer ... However, if a patient still has cancer cells at the time of surgery or residual cancer are identified after surgery, there are additional treatment options available to ...

I think in HER2+ breast cancer ... triple-negative breast cancer where there's residual disease; that's a trickier problem. That's a place where if you detect something, it may be there, it ...